港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

生物医药B类股

585.569

+7.6361.32%

涨家数：17

跌家数：13

平家数：4

市盈率：- -

高：598.497

开：578.227

低：578.109

收：577.933

成交量：6,124.09万

成交额：21.05亿

市值：3,730.90亿

流通市值：3,328.74亿

数据加载中...

总览新闻资讯

汉方制药独家产品卷入行贿案上个月刚披露H股招股书

康方生物(09926)出现大手买入8.1万股，成交价$124.3，涉资1.007千万

阿斯达克财经

《大行》华泰证券：吉利德收购Ouro反映康诺亚(02162.HK)平台价值

阿斯达克财经

强业绩提振，港股通创新药逆市续涨，520880收复20日线！乐普生物-B绩后狂飙14%

港股异动 | 基石药业-B(02616)再涨超4% 核心商业化产品舒格利单抗获ESMO指南【I, A】级推荐

港股沛嘉医疗-B早盘涨超6%

每日经济新闻

国家医保局医药服务管理司司长黄心宇：长护险制度建设可以从市地级统筹先起步不搞“齐步走”、“一刀切”

开拓药业－Ｂ(09939)股价下跌5.085%，现价港币$2.8

阿斯达克财经

港股生物医药板块涨幅居前，康方生物涨超5%，科伦博泰生物涨超4%

老虎资讯综合

快讯：恒指低开0.27% 科指跌0.68% 科网股走弱创新药概念高开快手跌超9%

【券商聚焦】中信建投：医疗器械板块拐点来临，26年业绩改善个股存在业绩估值修复机会

云顶新耀(01952)2025年股东净亏损同比收窄71.4%

《业绩》亚盛医药－Ｂ(06855.HK)去年亏损扩大至12.43亿人民币

阿斯达克财经

沛嘉医疗-B(09996.HK)：董事会董事长张一博士拟于公开市场继续增持股份

亚盛医药-B(06855)双引擎驱动高增长，耐立克销售同比大增81%

云顶新耀(01952)发布年度业绩收益17.07亿元同比大增141.51% 耐赋康®销售驱动强劲增长

智通财经网

东阿阿胶副总裁李庆川辞职；默克拟收购美国生物技术公司Terns | 医药早参

每日经济新闻

康宁杰瑞制药-B财年亏损1.139亿元人民币

康宁杰瑞制药-B(09966)发布年度业绩，年内亏损人民币1.14亿元同比盈转亏

同源康医药-B(02410)将于2026年AACR年会上展示五个创新药项目的研究成果

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK1574/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物医药B类股","latestPrice":585.569,"timestamp":1774497595023,"preClose":577.93304,"halted":0,"volume":61240855,"delay":0,"changeRate":0.013212,"floatShares":0,"shares":0,"eps":0,"marketStatus":"午间休市","change":7.635925,"latestTime":"03-26 12:00:00","open":578.2267,"high":598.49725,"low":578.109,"amount":2104788508,"amplitude":0.035278,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774501200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1774488600000,1774497600000],[1774501200000,1774512000000]],"pbRate":5.179109,"peRate":-60.041027,"turnoverRate":0.002233,"increases":17,"decrements":13,"flats":3,"marketCap":373090137024,"floatMarketCap":332873897520},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":598.49725,"amplitude":0.035278,"preClose":577.93304,"low":578.109,"pbRate":"5.179109","latestPrice":585.569,"volume":61240855,"delay":0,"open":578.2267,"prevYearClose":556.26263,"prevWeekClose":560.669,"prevMonthClose":553.496,"prevQuarterClose":556.263,"fiveDayClose":571.212,"twentyDayClose":537.703,"sixtyDayClose":574.89,"secType":"PLATE","market":"HK","turnoverRate":0.002233,"peRate":-60.041027,"marketCap":373090137024,"floatMarketCap":332873897520,"timestamp":1774497595023,"nameCN":"生物医药B类股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":17,"down":13,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622887076","title":"汉方制药独家产品卷入行贿案 上个月刚披露H股招股书","url":"https://stock-news.laohu8.com/highlight/detail?id=2622887076","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622887076?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 11:37","pubTimestamp":1774496231,"startTime":"0","endTime":"0","summary":"中国经济网北京3月26日讯 国家医保局网站3月24日通报了“张某猛药品销售行贿案”。2024年10月，河北省秦皇岛市山海关区人民法院依法组成合议庭，适用普通程序公开开庭审理了张某猛行贿、对非国家工作人员行贿案。　　汉方制药于2月25日向港交所递交了招股书，拟于主板上市。据招股书显示，汉方制药成立于2004年，从事中医药产品研发、生产及销售业务。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202603/26/20260326934314.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202603/26/20260326934314.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260326/32100470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","01477","BK1191"],"gpt_icon":0},{"id":"2622880365","title":"康方生物(09926)出现大手买入8.1万股，成交价$124.3，涉资1.007千万","url":"https://stock-news.laohu8.com/highlight/detail?id=2622880365","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622880365?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 11:34","pubTimestamp":1774496040,"startTime":"0","endTime":"0","summary":"[大手成交]康方生物(09926)在上午11:34出现大手买入，成交量为8.1万，成交价为港币$124.3，涉资1.007千万。至目前为止，股价升2.053%，今日最高价为$129.7，而最低价为$124.1，总成交量为880.26万股，总成交金额港币$11.197亿。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603265100/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603265100/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["IE00B5MMRT66.SGD","09926","LU0634319403.HKD","LU2476274720.SGD","LU0417516902.SGD","IE00BPRC5H50.USD","LU0540923850.HKD","BK1161","LU0348825331.USD","LU0348783233.USD","LU0561508036.HKD","LU2399975544.HKD","LU1794554557.SGD","LU0348827113.USD","IE00B543WZ88.USD","LU0348735423.USD","LU1961090484.USD","LU0417516738.SGD","BK1574","LU0348766576.USD","LU0348784397.USD","LU0417516571.SGD","LU2476274308.USD","LU0348767384.USD","LU1720050803.USD","LU2778985437.USD","LU2488822045.USD"],"gpt_icon":0},{"id":"2622887191","title":"《大行》华泰证券：吉利德收购Ouro反映康诺亚(02162.HK)平台价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2622887191","media":"阿斯达克财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622887191?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 11:21","pubTimestamp":1774495260,"startTime":"0","endTime":"0","summary":"华泰证券发表报告指，康诺亚-B公告吉利德将以16.75亿美元首付款、5亿美元里程碑并购Ouro，后者为承载CM336海外权益的NewCo。交易完成后，康诺亚依据Ouro股权将取得2.5亿元首付款及7,000万美元里程碑，同时继续享有CM336的销售分成权利。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220419164250683_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220419164250683_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512718/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512718/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0276","LU0531971595.HKD","BK1583","LU1934453819.USD","LU0164865239.USD","LU2148510915.USD","LU1064131003.USD","BK1574","BK1161","LU1328615791.USD","LU0871576103.HKD","LU1580142542.USD","BK0028","BK1587","LU1781817850.SGD","02162","601688","BK0188","LU1808992512.USD","BK0183","LU1979443071.USD","LU0039217434.USD","BK0012","LU1064130708.USD"],"gpt_icon":0},{"id":"2622882066","title":"强业绩提振，港股通创新药逆市续涨，520880收复20日线！乐普生物-B绩后狂飙14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622882066","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622882066?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 11:03","pubTimestamp":1774494180,"startTime":"0","endTime":"0","summary":"3月26日，港股通医药再度逆市表现，100%创新药研发标的——港股通创新药ETF华宝、港股医疗核心资产——港股通医疗ETF华宝双双高开，一度携手涨超1%！520880量价齐升，盘中收复20日线，实时成交超2亿元。　　创新药多股领跑，乐普生物-B盘中飙升逾14%站上半年线，领涨所有港股通标的。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-03-26/doc-inhshtfa2929921.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","VXUS","520880","06978","BK1574","02157","BK4585","BK4588","159992"],"gpt_icon":0},{"id":"2622821058","title":"港股异动 | 基石药业-B(02616)再涨超4% 核心商业化产品舒格利单抗获ESMO指南【I, A】级推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2622821058","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622821058?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 10:53","pubTimestamp":1774493593,"startTime":"0","endTime":"0","summary":"消息面上，3月25日，基石药业-B发布公告，公司核心商业化产品舒格利单抗获得欧洲肿瘤内科学会指南的级推荐。2025年2月，舒格利单抗联合化疗已获得ESMO《非驱动基因阳性转移性非小细胞肺癌动态临床指南》的推荐，用于鳞状及非鳞状IV期非小细胞肺癌双适应症的一线治疗。至此，舒格利单抗在欧盟及英国获批的两项肺癌适应症均已被纳入ESMO指南，充分体现了其临床价值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419292.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4588","BK1574","BK4585","02616","VXUS"],"gpt_icon":0},{"id":"2622444882","title":"港股沛嘉医疗-B早盘涨超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622444882","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622444882?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 10:47","pubTimestamp":1774493260,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月26日，沛嘉医疗-B(09996.HK)早盘涨超6%，截至发稿涨6.69%，报6.06港元，成交额1185.39万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603263685222031.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603263685222031.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159891","09996","BK4585","BK1100","BK4588","BK1583","VXUS","BK1574"],"gpt_icon":0},{"id":"2622882934","title":"国家医保局医药服务管理司司长黄心宇：长护险制度建设可以从市地级统筹先起步 不搞“齐步走”、“一刀切”","url":"https://stock-news.laohu8.com/highlight/detail?id=2622882934","media":"金融一线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622882934?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 10:46","pubTimestamp":1774493160,"startTime":"0","endTime":"0","summary":"3月26日金融一线消息，国务院新闻办公室举行新闻发布会，介绍加快建立长期护理保险制度有关情况。国家医保局医药服务管理司司长黄心宇在国新办新闻发布会上表示，《关于加快建立长期护理保险制度的意见》规定用三年左右的时间，基本建立适应我国基本国情的长期护理保险制度。到2028年底，这项制度要在全国基本上全面覆盖。\n　　黄心宇指出，从统筹层次上，可以从市地级统筹先起步，也可以根据当地实际情况探索省级统筹。有条件的市地可以先行，不具备条件的市地可以先夯实条件之后再实施，总的来说是不搞“齐步走”、不搞“一刀切”。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：秦艺","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jryx/insurance/2026-03-26/doc-inhshnwy0399508.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1574","09939","159938","BK1515"],"gpt_icon":0},{"id":"2622882993","title":"开拓药业－Ｂ(09939)股价下跌5.085%，现价港币$2.8","url":"https://stock-news.laohu8.com/highlight/detail?id=2622882993","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622882993?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 10:34","pubTimestamp":1774492440,"startTime":"0","endTime":"0","summary":"[下跌股]开拓药业－Ｂ(09939) 股价在上午10:34比前收市价下跌5.085%，现股价为港币$2.8。至目前为止，今日最高价为$2.95，而最低价为$2.8。总成交量为54.8万股，总成交金额为港币$156.63万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725131625844_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725131625844_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2603261531/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2603261531/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","BK1515","BK1161","09939"],"gpt_icon":0},{"id":"1112843274","title":"港股生物医药板块涨幅居前，康方生物涨超5%，科伦博泰生物涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1112843274","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112843274?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 09:54","pubTimestamp":1774490076,"startTime":"0","endTime":"0","summary":"3月26日，$生物(000504)$医药板块涨幅居前，$康方生物(09926)$涨超5%，$科伦博泰(06990)$生物涨超4%，$泰格医药(03347)$、$荣昌生物(09995)$涨超3%，$药明康德(02359)$、$君实生物(01877)$等个股跟涨","market":"us","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516902.SGD","LU0348784397.USD","LU1961090484.USD","LU0348766576.USD","09926","02162","09995","BK4588","BK4581","LU2778985437.USD","LU1720050803.USD","01877","LU2476274308.USD","IE00B5MMRT66.SGD","BK1161","IE00BPRC5H50.USD","BK1574","LU0348783233.USD","LU0540923850.HKD","LU0348767384.USD","LU0417516738.SGD","BK4585","LU0634319403.HKD","LU2476274720.SGD","LU0348735423.USD","LU0561508036.HKD","LU2488822045.USD","LU2399975544.HKD","LU1794554557.SGD","LU0348827113.USD","IE00B543WZ88.USD","LU0348825331.USD","LU0417516571.SGD","03347"],"gpt_icon":0},{"id":"2622813298","title":"快讯：恒指低开0.27% 科指跌0.68% 科网股走弱 创新药概念高开 快手跌超9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622813298","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622813298?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 09:20","pubTimestamp":1774488000,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　美股周三表现向上，中东局势有缓和迹象，油价由高位回落，带动大市气氛，三大指数均录得升幅收市。美元先跌后回升，美国十年期债息回落至4.33厘水平，金价反复向好，油价先跌后回稳。\n　　今日港股三大指数集体低开，恒指开盘跌0.27%，报25267.16点，恒科指跌0.68%，国企指数跌0.41%。盘面上，科网股涨跌不一，京东涨超2%，快手跌超9%，哔哩哔哩跌超1%；创新药概念股活跃，乐普生物涨超6%；汽车股部分走弱，蔚来跌超2%。\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：郝欣煜","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-03-26/doc-inhshnwy0334896.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0211977185.USD","LU1251922891.USD","LU1720050803.USD","LU1303224171.USD","HSTECH","LU0359201885.HKD","LU0572944931.SGD","BK1610","BK1590","HHImain","LU0359201612.USD","LU1719994722.HKD","MCHmain","BK1161","LU0348766576.USD","81024","BK1591","LU0348767384.USD","01024","LU2097828474.EUR","LU0326950275.SGD","LU1794554557.SGD","LU0588546209.SGD","LU2097828714.EUR","LU0210526637.USD","BK1574","LU2097828631.EUR","BK1615","LU0456827905.SGD","BK1608","513600","LU0051755006.USD","LU1770034418.SGD","LU0140636845.USD","LU0593848301.USD","LU0327786744.USD","LU0244354667.USD","LU1188198961.HKD","LU0359202008.SGD","LU1023057109.AUD","LU2097828557.USD","LU0307460666.USD","BK1575","BK1095","LU0463099449.HKD","LU2097828805.USD","02833","HSI"],"gpt_icon":0},{"id":"2622818008","title":"【券商聚焦】中信建投：医疗器械板块拐点来临，26年业绩改善个股存在业绩估值修复机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2622818008","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622818008?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 09:18","pubTimestamp":1774487918,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投表示，医疗器械板块拐点来临，26年业绩改善个股存在业绩估值修复机会。建议持续关注市场空间大、国产化率低的创新器械赛道，以及并购重组、脑机接口、AI医疗、手术机器人、外骨骼机器人等主题方向的投资机会。潜在催化较多的方向有望出现涨幅数倍的个股，未来AI医疗、脑机接口等也有望成为投资人重点关注的新科技方向。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977292","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06826","BK1593","BK1574","601066","BK1571","BK1591","09997","BK1584","BK1502","BK1583","LU0173614495.USD","159883","01066","01302","BK1615","BK1142","BK1100","09996","BK1610","BK1600","02190","BK1222","02235","BK1515","BK1589","BK1585","BK1617","LU0287142896.SGD","BK1247","02252","BK1587","BK1501","BK1189","00853","BK1161","00241","BK0276"],"gpt_icon":0},{"id":"2622198889","title":"云顶新耀(01952)2025年股东净亏损同比收窄71.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622198889","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622198889?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 09:04","pubTimestamp":1774487064,"startTime":"0","endTime":"0","summary":"金吾财讯 | 云顶新耀(01952)公告发布，截至2025年12月31日止，公司母公司拥有人应占净亏损为2.98亿元(人民币，下同)，同比减亏71.4%，每股基本净亏损0.89元，同比减亏72.5%。期内，录得收益17.07亿元，同比增长1.41倍；毛利润11.82亿元，同比增长1.24倍。期内，集团研发开支5.11亿元，分销及销售开支7.81亿元，一般行政开支2.77亿元。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/MGVkMTYyODU4OTM2NDU2Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MGVkMTYyODU4OTM2NDU2Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977287","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","01952","BK1583"],"gpt_icon":0},{"id":"2622886079","title":"《业绩》亚盛医药－Ｂ(06855.HK)去年亏损扩大至12.43亿人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2622886079","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622886079?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 08:52","pubTimestamp":1774486320,"startTime":"0","endTime":"0","summary":"亚盛医药－Ｂ(06855.HK) 公布截至去年12月底止全年业绩，营业额5.74亿元人民币(下同)，按年跌41.5%。亏损扩大至12.43亿元，上年同期蚀4.05亿元；每股亏损3.49元。不派末期息。(ca/w)(港股报价延迟最少十五分钟。沽空资料截至 2026-03-25 16:25。)过往派息公布日期派息事项派息内容2025/08/21中期业绩无派息2025/03/27末期业绩无派息2024/08/22中期业绩无派息2024/03/27末期业绩无派息AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20191016100749692_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20191016100749692_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512620/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512620/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["MCNHmain","CYB","06855","BK1574","CNHmain","UCmain","MUCmain","BK1161"],"gpt_icon":0},{"id":"2622883271","title":"沛嘉医疗-B(09996.HK)：董事会董事长张一博士拟于公开市场继续增持股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2622883271","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622883271?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 07:37","pubTimestamp":1774481825,"startTime":"0","endTime":"0","summary":"格隆汇3月26日丨沛嘉医疗-B(09996.HK)发布公告，董事会获悉，执行董事、首席执行官兼董事会董事长张一博士(“张博士”)透过其所控制的公司，自2026年3月26日起拟于公开市场上继续购买公司股份。是次持股增加合共代价预期不超过1500万港元。\r\n\r\n　　经张博士告知，持股增加反映其对公司内在价值的认可，以及其对公司发展前景及增长潜力的坚定信心。张博士将不排除根据适用法律及法规于适当时候进一步增加其于公司持股的可能性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260326/32098777.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1100","BK1574","159891","BK1583","09996"],"gpt_icon":0},{"id":"2622588314","title":"亚盛医药-B(06855)双引擎驱动高增长，耐立克销售同比大增81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622588314","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622588314?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 07:28","pubTimestamp":1774481290,"startTime":"0","endTime":"0","summary":"3月26日，头部创新药企业亚盛医药发布2025年全年业绩。作为公司首款商业化产品，耐立克在2025年迎来医保落地后的首个完整销售年份，销售额实现显著增长，达到4.35亿元人民币，同比大幅增长81%。公司第二款产品、中国首个上市的国产原创Bcl-2抑制剂利生妥自2025年7月获批后快速放量，截至报告期末的5个月内实现销售额7058万元人民币。业绩增长由已上市的两大核心产品“双引擎”高效驱动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419181.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"亚盛医药-B(06855)双引擎驱动高增长，耐立克销售同比大增81%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","BK1574","BK4139","06855","BK1161"],"gpt_icon":0},{"id":"2622883992","title":"云顶新耀(01952)发布年度业绩 收益17.07亿元 同比大增141.51% 耐赋康®销售驱动强劲增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2622883992","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622883992?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 07:23","pubTimestamp":1774481019,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云顶新耀 发布截至2025年12月31日止年度业绩，集团收益人民币17.07亿元，同比增长141.51%;股东应占亏损2.98亿元;研发开支5.11亿元;毛利11.82亿元，同比增长124.32%。收益增加主要由于耐赋康在已商业化市场的销售额继续上升所致。在中国市场，将耐赋康纳入国家医保药品目录为关键的增长动力，以致截至2025年12月31日止年度的耐赋康收益大幅增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"云顶新耀(01952)发布年度业绩 收益17.07亿元 同比大增141.51% 耐赋康®销售驱动强劲增长","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","BK1583","BK1161","01952"],"gpt_icon":0},{"id":"2622883390","title":"东阿阿胶副总裁李庆川辞职；默克拟收购美国生物技术公司Terns | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2622883390","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622883390?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 07:06","pubTimestamp":1774479983,"startTime":"0","endTime":"0","summary":"丨2026年3月26日星期四丨NO.1东阿阿胶副总裁李庆川辞职3月25日，东阿阿胶发布公告，称董事会近日收到李庆川提交的书面辞职报告，由于工作变动原因，李庆川申请辞去公司副总裁职务。辞职后，李庆川将担任公司党委副书记职务。截至公告日，李庆川持有公司20639股限制性股票，原定任期届满之日为2027年8月6日。点评：公司表示该项辞职不会影响公司相关工作的正常进行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603263684586713.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603263684586713.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0070302665.USD","LU2361044865.SGD","LU1291159041.SGD","LU1116320737.USD","SG9999014559.SGD","SG9999002232.USD","LU2089984988.USD","LU2468319806.SGD","MRK","BK4588","LU0006306889.USD","BK4585","LU2125154778.USD","BK4516","688197","LU2324357040.USD","SG9999002224.SGD","BK1574","IE00B1BXHZ80.USD","LU0861579265.USD","BK0183","SG9999001440.SGD","SG9999014575.USD","LU0985320562.USD","LU2106854487.HKD","LU1934455863.HKD","BK4550","IE00BN8TJ469.HKD","LU0203347892.USD","IE0009355771.USD","LU1929549753.HKD","BK1161","BK0028","IE00BLSP4239.USD","LU2361045086.USD","LU1201861249.SGD","LU0130102774.USD","LU0965509283.SGD","LU2023250504.SGD","LU0965509101.SGD","BK0188","LU1023059063.AUD","LU2023250843.SGD","LU0868494708.USD","LU0289739699.SGD","LU0942090050.USD","LU0477156953.USD","LU0266013472.USD","000423","LU1699723380.USD","LU1066051498.USD","IE0002141913.USD","LU0058720904.USD","IE00B4R5TH58.HKD","IE00BBT3K403.USD","LU1162221912.USD","BK4533","LU1989772923.USD","LU0648001328.SGD","IE00BFTCPJ56.SGD","LU1983299246.USD","SG9999013999.USD","LU0965508806.USD","LU2361044949.HKD","LU0320765489.SGD","LU0868494617.USD","LU0965509010.AUD","LU1093756168.USD","LU1037948897.HKD","LU0106261372.USD","SG9999014567.USD","SG9999001176.SGD","IE00BLSP4452.SGD","BK4534","LU1430594728.SGD","LU0211331839.USD","BK4559","LU2461242641.AUD","SG9999014542.SGD","LU1116320901.HKD","LU0203345920.USD","BK1515","LU1934455194.USD","LU1934455277.USD","LU2360032135.SGD","BK0175","LU0208291251.USD","IE00BSNM7G36.USD","SGXZ57979304.SGD","LU1066051811.HKD","SG9999001176.USD","LU0265550359.USD","BK0187","LU1066053197.SGD","LU1974910355.USD","LU0234572021.USD","LU0238689110.USD","BK0239","LU1057294990.SGD","LU0432979614.USD","LU1061106388.HKD","LU2112291526.USD","LU0122379950.USD","LU1571399168.USD","LU1585245621.USD","LU1035773651.USD","LU2125154935.USD","600812","SG9999014674.SGD","SG9999015341.SGD","BK4007","LU1917777945.USD","IE00BJJMRZ35.SGD","LU0265550946.USD","LU1069347547.HKD","IE00B2B36J28.USD","09939","LU1941712264.USD","LU0098860793.USD","LU1037948541.HKD","LU0320765646.SGD","LU1989772840.SGD","LU1989771016.USD","LU0130517989.USD","LU1066051225.USD","LU0980610538.SGD","BK0196","LU1093756325.SGD","SG9999015358.SGD","BK0010","IE00BJT1NW94.SGD","IE000M9KFDE8.USD","LU1941712348.USD"],"gpt_icon":0},{"id":"1153293212","title":"康宁杰瑞制药-B财年亏损1.139亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1153293212","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153293212?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 23:41","pubTimestamp":1774453268,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B（9966.HK）公布最新财年业绩，录得净亏损达1.139亿元人民币。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09966","BK1161"],"gpt_icon":0},{"id":"2622841070","title":"康宁杰瑞制药-B(09966)发布年度业绩，年内亏损人民币1.14亿元 同比盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2622841070","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622841070?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 23:14","pubTimestamp":1774451655,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B(09966)发布截至2025年12月31日止年度业绩，该公司取得收入人民币5.66亿元，同比减少11.54%;年内亏损人民币1.14亿元，同比盈转亏;每股亏损人民币0.12元。公告称，研发开支由截至2024年12月31日止年度的人民币4.04亿元增加至截至2025年12月31日止年度的人民币5.72亿元，主要由于(i)正在进行的临床试验数目增加;(ii)公司临床研究规模的扩大;及(iii)公司候选药物的临床试验进展。下表列载于所示年度按性质划分的研发开支明细。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419120.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09966","BK1574","UCmain","MCNHmain","CNHmain","CYB","MUCmain","BK1161"],"gpt_icon":0},{"id":"2622072086","title":"同源康医药-B(02410)将于2026年AACR年会上展示五个创新药项目的研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2622072086","media":"智通财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622072086?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 22:42","pubTimestamp":1774449755,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同源康医药-B(02410)发布公告，本公司将于2026年美国癌症研究协会(AACR)年会壁报环节展示TY-0609(CDK4抑制剂)、TY-2699a(CDK7抑制剂 )、 TY-2719(EGFR/FAK(PROTAC)抑制剂)、PI3Kα(PI3Kα抑制剂)、TY-1054 (YAP-TEAD抑制剂)五个在研创新药项目的研究进展和成果，此次展示的五个项目均为本公司自主研发的抗肿瘤小分子创新候选药物。本届AACR年会将于2026 年4月17日至22日在美国圣地亚哥举行，本公司参会壁报将分别于4月19日至4月 21日展示。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419089.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","09939","BK1574","159992","06978","02410","BK1161","159938"],"gpt_icon":0}],"pageSize":20,"totalPage":16,"pageCount":1,"totalSize":301,"code":"91000000","status":"200"}]}}